目的 探究克唑替尼聯(lián)合紫杉醇和順鉑治療間變淋巴瘤激酶（ALK）陽性非小細胞肺癌（NSCLC）的臨床療效。方法 選取2012年1月-2014年3月在榆林市第一醫(yī)院接受治療的ALK陽性NSCLC患者67例，隨機分為對照組（33例）和治療組（34例）。對照組靜脈滴注紫杉醇注射液175 mg/m²，1次/d；并于停藥30 min后靜脈滴注順鉑注射液75 mg/m²，1次/d。治療組在對照組基礎(chǔ)上口服克唑替尼膠囊，1粒/次，2粒/d。兩組均治療2個月，并隨訪24個月。觀察兩組的臨床療效，比較兩組的血清腫瘤標志物、不良反應(yīng)和生存率。結(jié)果 治療后，對照組和治療組的有效率分別為27.27%、61.76%，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組癌胚抗原（CEA）、糖類抗原（CA125）和細胞角蛋白19片段（CYFRA21-1）水平均顯著降低，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05、0.01）；且治療組這些觀察指標的下降程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。隨訪后，對照組和治療組的死亡率分別為24.24%、14.71%，中位無進展生存期（PFS）分別為13、17個月，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 克唑替尼聯(lián)合紫杉醇和順鉑治療ALK陽性NSCLC具有較好的臨床療效，可降低血清腫瘤標志物水平，延長中位PFS，提高患者的生存率，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical effect of crizotinib combined with paclitaxel and cisplatin in treatment of anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC). Methods Patients (67 cases) with NSCLC in the First Hospital of Yulin from January 2012 to March 2015 were randomly divided into control group (33 cases) and treatment group (34 cases). Patients in the control group were iv administered with Paclitaxel Injection 175 mg/m², once daily. And Patients in the control group were also iv administered with Cisplatin Injection 75 mg/m², once daily. Patients in the treatment group were po administered with Crizotinib Capsules on the basis of the control group, 1 grain/time, twice daily. Patients in two groups were treated for 2 months, and followed up for 24 months. After treatment, the clinical efficacies were evaluated, and serum tumor marker, adverse reaction, and survival rate in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 27.27% and 61.76%, respectively, and there was difference between two groups (P<0.05). After treatment, the levels of CEA, CA125, and CYFRA21-1 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05, 0.01). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After follow-up, the mortality rate in the control and treatment groups were 24.24% and 14.71%, respectively, the median PFS in the control and treatment groups were 13 and 17 months, respectively, and there was difference between two groups (P<0.05). Conclusion Crizotinib combined with paclitaxel and cisplatin has clinical curative effect in treatment of ALK positive NSCLC, can decrease serum tumor marker, extend median PFS, and improve survival rate, which has a certain clinical application value.